| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 12/28/2006 | US20060292192 Pharmaceutical and cosmetic formulations |
| 12/28/2006 | US20060292191 Use of nanodispersions in pharmaceutical end formulations |
| 12/28/2006 | US20060292190 Amelioration of vitrectomy-induced cataracts |
| 12/28/2006 | US20060292189 Ophthalmic solution with a flavoring agent as a dosing indicator and method for indicating dosage of an ophthalmic solution |
| 12/28/2006 | US20060292188 Ophthalmic solution with a flavoring agent |
| 12/28/2006 | US20060292187 Nerve construct containing living stretch-grown nervous tissue |
| 12/28/2006 | US20060292186 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
| 12/28/2006 | US20060292185 Topical skin preparations for treatment of skin aging comprising a testosterone ester |
| 12/28/2006 | US20060292184 Bioadhesive liquid composition which is substantially free of water |
| 12/28/2006 | US20060292183 forming oil in water emulsions containing drugs by heating nanostructure particle size matrices, surfactants and drugs, then cooling while stirring |
| 12/28/2006 | US20060292181 Method for Inducing a Cell-Mediated Immune Response and Improved Parenteral Vaccine Formulations Thereof |
| 12/28/2006 | US20060292135 Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl |
| 12/28/2006 | US20060292133 Use of lactobacillus salivarius |
| 12/28/2006 | US20060292120 COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS |
| 12/28/2006 | US20060292118 Hollow nanoparticles of protein and drug using the same |
| 12/28/2006 | US20060292117 Improved rAAv vectors |
| 12/28/2006 | US20060292085 Medicaments |
| 12/28/2006 | US20060292084 Process for Cleaning Hard Gelatine Capsules |
| 12/28/2006 | US20060292083 Inhalation compositions with high drug ratios |
| 12/28/2006 | US20060292082 Dry powder inhaler |
| 12/28/2006 | US20060292081 Methods for preparing pharmaceutical compositions |
| 12/28/2006 | US20060290882 Laminated contact lens |
| 12/28/2006 | US20060289556 Sheeted cleaning medium and dispenser |
| 12/28/2006 | US20060288834 Process and device for manufacturing a product from strip tape, especially for manufacturing a medicinal and/or active substance-containing product as well as fillable containers or sealed-margin bags |
| 12/28/2006 | US20060288830 Process and device for manufacturing a product from strip tape, especially for manufacturing a medicinal and/or active substance-containing product as well as fillable containers or sealed-margin bags |
| 12/28/2006 | DE19940239B4 Pflege- und/oder Heilverband, insbesondere zur Intensivtherapierung von Langzeit-Hauterkrankungen bei Mensch und Tier Care and / or healing dressing, especially for Intensivtherapierung of long-term skin diseases in humans and animals |
| 12/28/2006 | DE102005028696A1 Use of auxiliary material comprising calcium stearate, magnesium stearate, stearic acid, cromoglycic acid and/or di-sodium-cromoglycate, active substance and carrier material, for adjusting abrasion firmness of hardened preparation |
| 12/28/2006 | CA2852537A1 Permeant delivery system and methods for use thereof |
| 12/28/2006 | CA2646780A1 Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
| 12/28/2006 | CA2616557A1 Stable pharmaceutical compositions including motilin-like peptides |
| 12/28/2006 | CA2613247A1 Prophylactic or therapeutic agent for corneal/conjunctival disease |
| 12/28/2006 | CA2612738A1 Solid pharmaceutical composition comprising (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chroman |
| 12/28/2006 | CA2612456A1 Gel compositions for topical administration |
| 12/28/2006 | CA2612384A1 Nanoparticulate azelnidipine formulations |
| 12/28/2006 | CA2612380A1 Estrogen compositions for vaginal administration |
| 12/28/2006 | CA2612309A1 Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent |
| 12/28/2006 | CA2612090A1 Tablet containing hardly soluble active ingredient |
| 12/28/2006 | CA2612044A1 Emetic embedded capsule |
| 12/28/2006 | CA2611898A1 Pharmaceutical compositions of hops resins |
| 12/28/2006 | CA2610909A1 Manufacturing process for tigecycline |
| 12/28/2006 | CA2609251A1 Pharmaceutical compositions and use thereof |
| 12/28/2006 | CA2608930A1 Pharmaceutical formulations for minimizing drug-drug interactions |
| 12/28/2006 | CA2607600A1 Modified and immediate release memantine bead formulation |
| 12/27/2006 | EP1736469A2 Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-Fluorophenyl)ethyl]-4-piperidinemethanol |
| 12/27/2006 | EP1736156A1 STABILIZED 4-AMINO-5-CHLORO-N-¬(1R,3r,5S)-8-METHYL-8- AZABICYCLO¬3.2.1|OCT-3-YL|-2-¬1-METHYLBUT-2-YNYLOXY|-BENZAMIDE CONTAINING COMPOSITION |
| 12/27/2006 | EP1736150A2 Sertraline salts and sustained-release dosage forms of sertraline |
| 12/27/2006 | EP1736148A1 Medical emulsion of perfluororganic compounds and method for the production thereof |
| 12/27/2006 | EP1736147A2 Non-chlorofluorocarbon aerosol formulations |
| 12/27/2006 | EP1736146A1 Nicotine transdermal delivery system |
| 12/27/2006 | EP1736145A2 Beneficial agent delivery system with membrane plug |
| 12/27/2006 | EP1736144A2 Orally disintegrable tablets |
| 12/27/2006 | EP1736143A1 Process for producing medicine |
| 12/27/2006 | EP1736136A1 Enzyme inhibiting spray skin barrier compositions |
| 12/27/2006 | EP1736060A2 Encapsulated agglomeration of microcapsules and method for the preparation thereof |
| 12/27/2006 | EP1735413A1 Compositions containing interestified lipids and phytosterol ester, and related methods, with health and nutrition promoting characteristics |
| 12/27/2006 | EP1735377A1 Biopolymer compositions and products thereof |
| 12/27/2006 | EP1735020A1 Injectable crosslinked and uncrosslinked alginates and the use thereof in medicine and in cosmetic surgery |
| 12/27/2006 | EP1735009A2 iRNA AGENTS TARGETING VEGF |
| 12/27/2006 | EP1735007A2 Cyclodextrin inclusion complexes of pyrimidine-2,4,6-triones |
| 12/27/2006 | EP1735006A1 Polymer particles containing active agents |
| 12/27/2006 | EP1735005A1 Method for encapsulation of orally ingested materials to alter the site of digestion, site of action, or stability |
| 12/27/2006 | EP1735004A1 Dietary supplement and method of processing same |
| 12/27/2006 | EP1735003A2 Pharmaceutical compositions based on anticholinergics and ccr2 receptor antagonists |
| 12/27/2006 | EP1734993A2 Apparatus and method for transdermal delivery of influenza vaccine |
| 12/27/2006 | EP1734987A2 Interferon-beta for anti-virus therapy for respiratory diseases |
| 12/27/2006 | EP1734984A2 Compositions and methods for topical diagnostic and therapeutic transport |
| 12/27/2006 | EP1734971A1 Polymer-based sustained release device |
| 12/27/2006 | EP1734965A1 New compositions and methods for maintaining eyelid hygiene |
| 12/27/2006 | EP1734945A1 A composition containing a complex comprising a metal ion and a carboxylate ligand having anti-inflammatory activity |
| 12/27/2006 | EP1734938A1 Insulin highly respirable microparticles |
| 12/27/2006 | EP1734937A1 Nanoparticle formulations of platinum compounds |
| 12/27/2006 | EP1734936A2 Amphiphilic star-like or scoprion-like macromolecules, various compositions and uses thereof |
| 12/27/2006 | EP1734935A1 Poly (lactide-co-glycolide)-based sustained release microcapsules comprising a polypeptide and a sugar |
| 12/27/2006 | EP1734934A1 Dosage form having polymorphic stability |
| 12/27/2006 | EP1734933A1 Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423) |
| 12/27/2006 | EP1734932A1 Pharmaceutical compositions comprising an amphiphilic starch |
| 12/27/2006 | EP1734931A2 Formulations of ramipril |
| 12/27/2006 | EP1734930A2 Low dose pharmaceutical products |
| 12/27/2006 | EP1734929A1 Microparticles for cell delivery |
| 12/27/2006 | EP1734928A2 Serum-stable amphoteric liposomes |
| 12/27/2006 | EP1734927A1 Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides |
| 12/27/2006 | EP1734926A2 Aqueous solutions comprising prednisolone and a cyclodextrin derivative |
| 12/27/2006 | EP1734925A2 Novel compositions for topical delivery |
| 12/27/2006 | EP1734924A1 Deferasirox dispersible tablets |
| 12/27/2006 | EP1734923A1 Zinc preservative composition and method of use |
| 12/27/2006 | EP1734921A2 Coated tablet formulation and method |
| 12/27/2006 | EP1734920A2 Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
| 12/27/2006 | EP1653963B1 Nasal pharmaceutical piribedil composition |
| 12/27/2006 | EP1575551A4 Nutritional supplement composition and method |
| 12/27/2006 | EP1534682B1 Novel molecules derived from noraporphine |
| 12/27/2006 | EP1534282B1 Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
| 12/27/2006 | EP1487892B1 Amphiphilic diblock, triblock and star-block copolymers and their pharmaceutical compositions |
| 12/27/2006 | EP1363730B1 Process for making microcapsules involving phase inversion |
| 12/27/2006 | EP1335710B1 Soft capsules comprising a starch mixture having a reduced branching degree |
| 12/27/2006 | EP1284717B1 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base |
| 12/27/2006 | EP1231898B1 Apparatus and method for preparing microparticles |
| 12/27/2006 | EP1225870B1 Composition and method of cancer antigen immunotherapy |
| 12/27/2006 | EP1216028B1 Biodegradable excipient systems for therapeutically active substances and method for producing the same |
| 12/27/2006 | EP1185618B1 A bacterial strain, processed plant extracts and probiotic compositions for human and veterinary use |
| 12/27/2006 | EP1083885B1 Delavirdine tablet formulation |